Biotechnology

Pacira BioSciences Acquisitions Biogen Avalo Therapeutics Neumora Therapeutics Cancer Treatment

AbbVie to Acquire Capstan Therapeutics for $2.1 Billion to Boost In Vivo CAR-T Portfolio

Pending Hart-Scott-Rodino approval, AbbVie will integrate Capstan’s Phase 1 CAR-T candidate with its targeted lipid nanoparticle platform for precise RNA delivery.

6 ARTICLES

2mo ago

Biogen Boosts Profit Forecast as Alzheimer's Drug Leqembi Gains Traction

Biotechnology

AbbVie to Acquire Capstan Therapeutics for $2.1 Billion to Boost In Vivo CAR-T Portfolio

Merck KGaA Confirms $3.9 Billion Acquisition of SpringWorks Therapeutics

Sanofi Secures $1.9 Billion Deal for Dren Bio’s Innovative Autoimmune Therapy

Neumora’s Depression Drug Fails to Meet Goals in Key Phase 3 Trial

Biogen Boosts Profit Forecast as Alzheimer's Drug Leqembi Gains Traction